| CASE REPORT |
|
| Year : 2022 | Volume
: 19
| Issue : 1 | Page : 36-38 |
|
|
Newer drug for the resistant bug: A case report of spondylodiscitis with Klebsiella pneumoniae producing carbapenemase managed successfully with ceftazidime-avibactam
Sushma Krishna1, Neha Mishra2, Nikhil Nediyan Chath3, Gowrishankar Swamy3, Shrikanth Kanchana Pala3
1 Department of Microbiology, Central Laboratory, People Tree Hospitals, Bengaluru, Karnataka, India
2 Department of Infectious Diseases, Manipal Hospitals, Bengaluru, Karnataka, India
3 Department of Spine Surgery and Orthopedics, People Tree Hospitals, Bengaluru, Karnataka, India
Correspondence Address:
Sushma Krishna
Department of Microbiology, Central Laboratory, People Tree Hospitals, Yeshwanthpur, Bengaluru - 560 022, Karnataka
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/joasis.joasis_2_22
|
|
|
Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae are multidrug resistant organisms that have been increasingly recognized to cause infections with high mortality. The therapeutic options available for treating such infections stand severely compromised. The use of ceftazidime-avibactam in bacteremia and other infections by these organisms has been reported. We report a case of spondylodiscitis caused by KPC-KP diagnosed by pan-bacterial DNA screen and successfully treated with this relatively newer antibiotic. This report highlights the importance of the utility of molecular diagnostic tests in routine practice.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
